News

Moderna, Inc.: Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18-59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...